Fortrea Holdings Inc
FTRE
ISIN null / Valor 127734378
Fortrea Holdings Inc
UMushroom community rating:
About company
Fortrea Holdings Inc. operates as a global provider in the healthcare sector, specializing in a wide range of services that support the lifecycle of clinical trials from Phase I through IV. The company's offerings encompass clinical pharmacology, patient access solutions, and other essential services aimed at facilitating the development and delivery of healthcare innovations. Fortrea distinguishes itself by partnering with both emerging and established biopharmaceutical, as well as medical device and diagnostic companies, leveraging its expertise to advance healthcare solutions worldwide. With a workforce of over 19,000 professionals, Fortrea is committed to delivering customized clinical trial solutions through three primary delivery models: full service, functional service provision, or a hybrid approach. This tailored strategy enables the company to meet the diverse needs of its clients across nearly 100 countries, underscoring its role as a key player in driving global healthcare innovation.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (11.10.2025):
Fortrea Holdings Inc reported its financial results for the second quarter of 2025, demonstrating revenue growth to $710.3 million. Despite a GAAP net loss of $374.9 million, the company showed resilience with an adjusted EBITDA of $54.9 million and raised its full-year revenue guidance.
Revenue Growth
Fortrea Holdings Inc achieved revenues of $710.3 million in the second quarter of 2025, up from $662.4 million in the same quarter last year, reflecting strong market demand and business expansion.
Net Loss and Goodwill Impairment
The company reported a GAAP net loss of $374.9 million, including a non-cash goodwill impairment charge of $309.1 million. This resulted in a diluted loss per share of $(4.14), compared to a loss of $(1.11) per share in Q2 2024.
Adjusted EBITDA
Fortrea Holdings Inc reported an adjusted EBITDA of $54.9 million for the second quarter of 2025, slightly decreasing from $55.2 million in the second quarter of 2024, highlighting stable operational performance.
Book-to-Bill Ratio and Backlog
The company maintained a backlog of $7,547 million with a book-to-bill ratio of 0.79x for the quarter, contributing to a trailing 12-month book-to-bill ratio of 1.10x, indicating steady future revenue streams.
Full-Year Guidance
Fortrea Holdings Inc raised its 2025 revenue guidance to a range of $2,600 million to $2,700 million and affirmed its adjusted EBITDA guidance, reflecting confidence in continued growth and operational efficiency.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
945 M
Market cap (USD)
797,823
Daily traded volume (Shares)
19.1 / 18.34
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Maryam Jaouad
EQUITIES OF THE SAME SECTOR
